NCEL vs MNDO Comparison

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.